Pınar Korkmaz
Pınar Korkmaz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
A. Boyvat
Dermatology Department Düziçi State Hospital Osmaniye Turkey
1 shared publication- Cagdas Boyvadoglu
Department of Dermatology, Ceyhan State Hospital, Adana, Turkey
1 shared publication - Erdem Taş
Dermatology Department, Gaziantep University Hospital Faculty of Medicine, Gaziantep, Türkiye
1 shared publication - Fatih Albayrak
Department of Rheumatology, Gaziantep University, 27310 Gaziantep, Turkey
1 shared publication - Goknur Ozaydin-Yavuz
Department of Dermatology and Venerology, Başakşehir Çam and Sakura City Hospital, Health Sciences University, 34480 Istanbul, Türkiye
1 shared publication - Hasan Ulusal
Department of Medical Biochemistry, Faculty of Medicine, Gaziantep Islam Science and Technology University, Gaziantep 27010, Türkiye
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Caleo in Rheumatology Quarterly
- Vol. 4 (2) , 128-132
Granulomatous Mastitis, Erythema Nodosum, and Arthritis Syndrome: Case Presentation and Literature Review
Granulomatous mastitis (GM) is an inflammatory breast disease that may rarely be accompanied by systemic manifestations such as erythema nodosum (EN) and arthritis. In recent years, the association of GM with EN, with or without arthritis, has been recognized as GMENA syndrome. This report presents a case of GMENA syndrome and reviews the published literature. A 26-year-old woman presented with swelling, erythema, pain, and discharge in the left breast. Initial evaluation suggested infectious mastitis, but prolonged antibiotic therapy was ineffective. During follow-up, bilateral ankle arthritis and pretibial EN developed. Laboratory tests showed marked systemic inflammation. Core needle biopsy demonstrated chronic granulomatous inflammation, and microbiological studies were negative. The GMENA syndrome was diagnosed after exclusion of alternative causes. Methylprednisolone led to rapid improvement in both breast and systemic manifestations. A review of published cases showed a similar pattern of unilateral breast involvement, EN, and frequent peripheral arthritis or arthralgia, with generally favorable responses to corticosteroid therapy. Granulomatous mastitis should be considered in patients with treatment-resistant inflammatory breast lesions accompanied by systemic findings such as EN and arthritis. Recognition of this clinical pattern may help avoid unnecessary antibiotic use and allow timely initiation of appropriate immunosuppressive treatment.
- 15 June 2026
- Published by Caleo in Rheumatology Quarterly
- Vol. 4 (2) , 128-132
Open AccessGranulomatous Mastitis, Erythema Nodosum, and Arthritis Syndrome: Case Presentation and Literature Review
Granulomatous mastitis (GM) is an inflammatory breast disease that may rarely be accompanied by systemic manifestations such as erythema nodosum (EN) and arthritis. In recent years, the association of GM with EN, with or without arthritis, has been recognized as GMENA syndrome. This report presents a case of GMENA syndrome and reviews the published literature. A 26-year-old woman presented with swelling, erythema, pain, and discharge in the left breast. Initial evaluation suggested infectious mastitis, but prolonged antibiotic therapy was ineffective. During follow-up, bilateral ankle arthritis and pretibial EN developed. Laboratory tests showed marked systemic inflammation. Core needle biopsy demonstrated chronic granulomatous inflammation, and microbiological studies were negative. The GMENA syndrome was diagnosed after exclusion of alternative causes. Methylprednisolone led to rapid improvement in both breast and systemic manifestations. A review of published cases showed a similar pattern of unilateral breast involvement, EN, and frequent peripheral arthritis or arthralgia, with generally favorable responses to corticosteroid therapy. Granulomatous mastitis should be considered in patients with treatment-resistant inflammatory breast lesions accompanied by systemic findings such as EN and arthritis. Recognition of this clinical pattern may help avoid unnecessary antibiotic use and allow timely initiation of appropriate immunosuppressive treatment.
- Open Access
- 26 September 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-6
Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.
- 26 September 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-6
Open AccessEffects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.
- 20 February 2023
- Published by Hitit University in Hitit Medical Journal
- Vol. 5 (1) , 59-61
Mortaliteyle Sonuçlanan Geç Başlangıçlı Warfarin Kaynaklı Cilt Nekrozu Olgusu
Warfarin-induced skin necrosis is a rare complication of warfarin therapy and is associated with high mortality. Here, we present a case of warfarin-induced skin necrosis, that was fatal in a 53-year-old female patient who was started on warfarin treatment 5.5 years ago due to atrial fibrillation and previous mitral valve surgery. Patients using warfarin should be evaluated for warfarin-induced skin necrosis when they present with skin lesions. Early diagnosis, early discontinuation of the drug, early initiation of supportive treatment can be life-saving.
- 20 February 2023
- Published by Hitit University in Hitit Medical Journal
- Vol. 5 (1) , 59-61
Mortaliteyle Sonuçlanan Geç Başlangıçlı Warfarin Kaynaklı Cilt Nekrozu Olgusu
Warfarin-induced skin necrosis is a rare complication of warfarin therapy and is associated with high mortality. Here, we present a case of warfarin-induced skin necrosis, that was fatal in a 53-year-old female patient who was started on warfarin treatment 5.5 years ago due to atrial fibrillation and previous mitral valve surgery. Patients using warfarin should be evaluated for warfarin-induced skin necrosis when they present with skin lesions. Early diagnosis, early discontinuation of the drug, early initiation of supportive treatment can be life-saving.
- 1 January 2021
- Published by Wiley in British Journal of Dermatology
- Vol. 184 (1) , 2
The importance of provided information in contact allergy: key predictors on the road to success in the control of allergic contact dermatitis
- 1 January 2021
- Published by Wiley in British Journal of Dermatology
- Vol. 184 (1) , 2
The importance of provided information in contact allergy: key predictors on the road to success in the control of allergic contact dermatitis